Compare Commvault Systems Inc (CVLT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Viatris Inc — how do they compare? Commvault Systems Inc trades at $151.12 (market cap $6.25B), while Viatris Inc trades at $17.38 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.2× Commvault Systems Inc's market cap, and Viatris Inc pays a 2.75% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Viatris Inc for 57 Days on average.
| CVLT | VTRS | |
|---|---|---|
Market Cap | $6.25B | $20.03B |
Volume | 632,727 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $176.52 | $18.27 |
52-Week Low | $75.18 | $9.74 |
Typical Hold Time | 17 Days | 57 Days |
Enterprise Value | $6.24B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.74, up 0.31% with strong bullish technical momentum. The stock shows robust earnings performance, beating estimates for three consecutive quarters, with Q3 2026 results pending. Recent business developments include AWS Data Competency achievement and expanded FedRAMP authorization, positioning the company for growth in AI-driven resilience markets.
The outlook remains positive with 54.5% analyst buy ratings and a $156.55 consensus target, though high valuation multiples and declining profit margins warrant caution. Key risks include competitive pressures in cybersecurity and execution challenges in maintaining growth momentum amid expanding AI capabilities.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
